Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Cholecystitis

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hyperpigmentation over the metacarpophalangeal joints and the malleoli in a case of hyaline fibromatosis syndrome with ANTXR2 mutations.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015

Same author

Dowling-Degos disease with mutations in POFUT1 is clinicopathologically distinct from reticulate acropigmentation of Kitamura.

The British journal of dermatology·2015

Same author

Long-term outcome in Japanese patients with lupus nephritis.

Lupus·2014

Same author

Electrostatic ion cyclotron and ion plasma waves in a symmetric pair-ion plasma cylinder.

Physical review letters·2014

Same author

Comprehensive screening for a complete set of Japanese-population-specific filaggrin gene mutations.

Allergy·2014

Same author

Application of nanoscale packed capillary liquid chromatography (75 μm id) and capillary zone electrophoresis/electrospray ionization mass spectrometry to the analysis of macrolide antibiotics.

Journal of the American Society for Mass Spectrometry·2013

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Psoriasis treated with ursodeoxycholic acid: three case reports.

S Itoh¹, M Kono, T Akimoto

¹Division of Hepatology, Chiba Central Medical Center, Chiba, Japan. s.itoh@ccmc.seikei-kai.or.jp

Clinical and Experimental Dermatology

|March 23, 2007

Summary

Nonalcoholic fatty liver disease (NAFLD) in three patients with psoriasis vulgaris improved with ursodeoxycholic acid (UDCA) treatment. UDCA may resolve psoriasis skin lesions by suppressing inflammatory mediators like phospholipase A(2).

More Related Videos

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

Published on: January 12, 2024

Related Experiment Videos

Last Updated: Jul 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

Published on: January 12, 2024

Area of Science:

Hepatology
Dermatology
Biochemistry

Background:

Psoriasis vulgaris is a chronic inflammatory skin condition.
Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent.
Both conditions share potential inflammatory pathways involving phospholipase A(2) (PLA(2)).

Observation:

Three Japanese patients presented with psoriasis vulgaris co-occurring with NAFLD.
These patients experienced significant resolution of skin lesions after NAFLD treatment with ursodeoxycholic acid (UDCA).

Findings:

Arachidonic acid metabolism via PLA(2) produces inflammatory eicosanoids implicated in psoriasis.
PLA(2) activity is elevated in psoriasis patients' serum and skin.
UDCA demonstrated inhibitory effects on group IIA PLA(2) (PLA(2)IIA) activity in cellular and clinical samples.

Implications:

UDCA treatment for NAFLD may offer a therapeutic benefit for psoriasis vulgaris.
Targeting PLA(2)IIA activity could be a novel strategy for managing psoriasis.
This suggests a potential link between liver health and dermatological inflammatory conditions.